Which genetic marker reduces the risk of nonresponse to antidepressant therapy in major depressive disorder (clinical depression)?

Updated: Aug 06, 2020
  • Author: Jerry L Halverson, MD; Chief Editor: David Bienenfeld, MD  more...
  • Print

A study of response to treatment with citalopram identified a significant association between treatment outcome and a marker in HTR2A, which is located at chromosome 13q14.2 and encodes the serotonin 2A receptor. The A allele (a single-nucleotide polymorphism in an intron of this gene) reduced the likelihood of nonresponse to citalopram in whites but not in the African-American population. An AA genotype resulted in a 16-18% reduction in absolute risk of being a nonresponder. [31]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!